Europe Palmoplantar Pustulosis (PPP) Market, By Disease Type (Type A and Type B), Severity (Mild-Moderate and Moderate-Severe), Diagnosis (Laboratory Tests, Skin Biopsy), Treatment (Emollients, Topical Steroids, Coal tar, Phototherapy), Population Type (Children and Adults), Route Of Administration (Oral, Topical and Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Europe Palmoplantar Pustulosis (PPP) Market Analysis and Size
The demand for palmoplantar pustulosis (PPP) has increased in both developing and in developed countries and the reason behind this is the rise in metal allergies. The exact cause of palmoplantar pustulosis is still unknown. This has been witnessed that it is the form of psoriasis and around 24% of patients have psoriasis on their body. This disease can occur in any age group. But mostly it occurs in women than men, and it is most frequently found in people between 40 and 60 years old. The treatment involved with this disorder does not cure it properly and is not always successful.
Data Bridge Market Research analyses a growth rate in the palmoplantar pustulosis (PPP) market in the forecast period 2023-2030. The expected CAGR of palmoplantar pustulosis (PPP) market is tend to be around 5.0% in the mentioned forecast period. The market is valued at USD 105.5 million in 2022, and it would grow upto USD 155.9 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Europe Palmoplantar Pustulosis (PPP) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Type A and Type B), Severity (Mild-Moderate and Moderate-Severe), Type (Diagnosis and Treatment), Population Type (Children and Adults), Route Of Administration (Oral, Topical and Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Market Players Covered
|
Novartis AG (Switzerland), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), AstraZeneca (U.K.), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Amgen inc. (U.S.), AnGes, Inc. (Japan), Johnson & Johnson Private Limited (U.S.), AbbVie Inc. (U.S.), Perrigo Company plc (Ireland), WOCKHARDT (India), Bausch Health Companies Inc. (Canada), Viatris Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Xiromed (U.S.) and Encube Ethicals Private Limited (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Palmoplantar pustulosis is a type of uncommon chronic pustular condition affecting the palms and soles. It is also known as pustulosis palmaris et plantaris. It is associated to a common skin condition, psoriasis. It has symptoms such as crops of sterile pustules occurring on one or both hands and feet. They are associated with thickened, red, scaly skin that easily develops painful cracks. It is a prolonged condition and the discomfort can be considerable, interfering with work and leisure activities.
Europe Palmoplantar Pustulosis (PPP) Market Dynamics
Drivers
- Availability of Diverse Treatments for PPP
There are numerous treatment options that are useful for treating patients suffering from PPP. Light therapy is a treatment that combines a medicine known as psoralen with a special form of ultraviolet light. Other treatments such as retinoids, biologic treatmnets such as adalimumab (Humira), brodalumab (Siliq), certolizumab pegol (Cimzia) etanercept (Enbrel). Other options include enzyme inhibitor, Methotrexate aryl hydrocarbon receptor (AHR) agonist are also useful. Thus, all these treatment options help in faster recovery of the patients impacting the market growth positively.
- Increasing Rate of Smoking
Cigarette smoking remains the top cause of preventable disease, disability, and death in the U.S., resulting in more than 480,000 deaths yearly, or around 1 in 5 deaths. In 2020, approximately 13 of every 100 U.S. adults aged 18 years or older smoked cigarettes. It has been witnessed that between 2001 and 2003, an average of 35% of U.S. adults between the age group of 18 to 29 years said they smoked cigarettes. That decreased to an average 12% between 2019 and 2022. Thus, this factor boosts the market growth.
Opportunities
- Incidence Rate of Autoimmune Disorders
Numerous studies have stated that all autoimmune diseases combined affect around 3% of the U.S. population, resulting in around 10 million people. Though many autoimmune diseases are rare, the National Institutes for Health (NIH) expects that they collectively affect between 5% and 8% percent of the U.S. population. Common ones include rheumatoid arthritis, lupus, Crohn's disease and ulcerative colitis. Numerous heredity factors also plays a major role in PPP development. According to the studies conducted, people suffering from autoimmune disorders such as thyroid disorders, arthritis, coeliac disease, and diabetes among others are more susceptible to palmoplantar pustulosis. Thus, this factor increases the market growth.
- Increasing Collaborations and Associations by Several Market Players
Numerous product launch and agreement are also initiated by many companies’ globally which are also increasing the palmoplantar pustulosis (PPP) market. For instance, F. Hoffmann-La Roche Ltd received approval for ACTPen in November 2018. It is a device that is widely used for accurate delivery of Actemra ((tocilizumab) for treating inflammatory symptoms related with palmoplantar pustulosis (PPP). It enabled the patients and physicians to observe the accurate drug dosage. This approval thus enabled the company to earn more revenue. Furthermore, Teligent received FDA approval for Clobetasol Propionate Cream USP, 0.05% in April 2018. It is a formulation particularly indicated for treatment of inflammatory symptoms related with palmoplantar pustulosis (PPP). Thus, this factor increases the market growth.
Restraints/Challenges
- Increased Expenditure of Treatment for PPP
The rising expenditure associated with the varied treatment and diagnostic options of PPP hinder the market growth. This disease demands prolonged treatment many a times which increases the overall cost which is not that feasible for people belonging to underdeveloped and developing regions. This impedes the market growth.
This palmoplantar pustulosis (PPP) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the palmoplantar pustulosis (PPP) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Europe Palmoplantar Pustulosis (PPP) Market Scope
The palmoplantar pustulosis (PPP) market is segmented on the basis of disease type, severity, diagnosis, treatment, population type, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Type A
- Type B
Severity
- Mild-Moderate
- Moderate-Severe
Diagnosis
- Laboratory Tests
- Skin Biopsy
Treatment
- Emollients
- Topical Steroids
- Coal tar
- Phototherapy
Population Type
- Children
- Adults
Route of Administration
- Oral
- Topical
- Parenteral
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Competitive Landscape and Europe Palmoplantar Pustulosis (PPP) Market Share Analysis
The palmoplantar pustulosis (PPP) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to palmoplantar pustulosis (PPP) market.
Key players operating in the palmoplantar pustulosis (PPP) market include:
- Novartis AG (Switzerland)
- Lilly (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- AstraZeneca (U.K.)
- GSK plc (U.K.)
- Merck & Co., Inc. (U.S.)
- Amgen inc. (U.S.)
- AnGes, Inc. (Japan)
- Johnson & Johnson Private Limited (U.S.)
- AbbVie Inc. (U.S.)
- Perrigo Company plc (Ireland)
- WOCKHARDT (India)
- Bausch Health Companies Inc.(Canada)
- Viatris Inc. (U.S.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Xiromed (U.S.)
- Encube Ethicals Private Limited (U.S.)
SKU-